U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT06992440) titled 'Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension' on May 13.

Brief Summary: Randomized, triple-masked, parallel arm clinical trial of empagliflozin versus placebo in pulmonary arterial hypertension (PAH) participants on stable approved PAH-targeted medical therapy.

Study Start Date: July, 2025

Study Type: INTERVENTIONAL

Condition: Pulmonary Arterial Hypertension

Intervention: DRUG: Empagliflozin 10 MG

10 mg tablet once daily

DRUG: Placebo

matching tablet once daily

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Gustavo A Heresi, MD, MS

Information provided by (Responsible Party): Gus...